{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:21:34Z","timestamp":1778638894324,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T00:00:00Z","timestamp":1515110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jiac.2017.12.006","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T13:20:40Z","timestamp":1516195240000},"page":"492-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118"],"prefix":"10.1016","volume":"24","author":[{"given":"Katsunori","family":"Yanagihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Kaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyomitsu","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Kosai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2017.12.006_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5009\/gnl.2014.8.1.1","article-title":"Clostridium difficile infection: a worldwide disease","volume":"8","author":"Burke","year":"2014","journal-title":"Gut Liver"},{"key":"10.1016\/j.jiac.2017.12.006_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2017.12.006_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2017.12.006_bib4","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"60","author":"Babakhani","year":"2011","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.jiac.2017.12.006_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C.\u00a0difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.12.006_bib6","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","article-title":"A\u00a0new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","author":"Tannock","year":"2010","journal-title":"Microbiology"},{"key":"10.1016\/j.jiac.2017.12.006_bib7","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1099\/00207713-44-4-812","article-title":"The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations","volume":"44","author":"Collins","year":"1994","journal-title":"Int J Syst Bacteriol"},{"issue":"Suppl 2","key":"10.1016\/j.jiac.2017.12.006_bib8","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","article-title":"Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin re-expression and recurrence of CDI","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.12.006_bib9","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In\u00a0vitro activities of OPT-80 and comparator drugs against intestinal bacteria","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.12.006_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40261-015-0291-9","article-title":"Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects","volume":"35","author":"Oshima","year":"2015","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jiac.2017.12.006_bib11","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard\u2014eighth edition","author":"Clinical Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.jiac.2017.12.006_bib12","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement (M100\u2013S25); superceded by new version (M100-S27)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.jiac.2017.12.006_bib13","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two Phase III trials of fidaxomicin against Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.12.006_bib14","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1128\/AAC.06305-11","article-title":"Comparative in\u00a0vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria","volume":"56","author":"Citron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.12.006_bib15","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s10096-014-2175-y","article-title":"Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008\u20132012, northern Taiwan","volume":"33","author":"Wang","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17303069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17303069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:57:52Z","timestamp":1761159472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17303069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1341321X17303069"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.12.006","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}